[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 36 of about 36
1. Manabe Y, Hamakawa Y, Sunami K, Ohta Y, Omori N, Abe K: Granulocytic sarcoma with orbit, cauda equina, muscle and peripheral nerve extension but without bone marrow involvement. Intern Med; 2007;46(9):633-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma with orbit, cauda equina, muscle and peripheral nerve extension but without bone marrow involvement.
  • We report a very rare case of granulocytic sarcoma (GS) with muscle and peripheral nerve extension but without bone marrow involvement.
  • Magnetic resonance imaging revealed bilateral orbital and cauda equina region tumors.
  • The characteristic cerebrospinal fluid (CSF) cytologic picture of CD14+, CD33+, CD4+, CD56+ and positive nonspecific erastase staining suggested the diagnosis of GS.
  • The patient underwent intrathecal and systemic chemotherapy, as if she had acute myeloid leukemia (AML).
  • [MeSH-major] Bone Marrow / pathology. Cauda Equina. Muscle Neoplasms / diagnosis. Neoplasms, Second Primary / diagnosis. Orbital Neoplasms / diagnosis. Peripheral Nervous System Neoplasms / diagnosis. Sarcoma, Myeloid / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17473505.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Varshney S, Bist SS, Gupta N, Bhatia R: Primary extraskeletal Ewing's sarcoma of the maxilla with intraorbital extension. Indian J Otolaryngol Head Neck Surg; 2007 Sep;59(3):273-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary extraskeletal Ewing's sarcoma of the maxilla with intraorbital extension.
  • Extraskeletal Ewing's sarcoma is often described as a tumour involving the soft tissues of the lower extremities and the paravertebral region.
  • Primary Ewing's sarcoma of the cranium is extremely rare, with only 17 cases reported so far [24].
  • Because of the above peculiarities a delay in diagnosis and thus in starting treatment is very probable in such cases.
  • Primary Ewings sarcoma rarely arises in the facial skeleton and only occasionally in the maxilla.
  • To date, there have been 22 cases of maxillary Ewing's sarcoma reported in the English-language literature [25].
  • We report here a new case of Ewing's sarcoma localized to the maxillary sinus, nose and the orbit, successfully treated by surgery, local high dosage radiotherapy and systemic chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Laryngol Otol. 1978 Nov;92(11):1007-24 [712227.001]
  • [Cites] Rhinology. 2005 Sep;43(3):225-8 [16218518.001]
  • [Cites] Bangladesh Med Res Counc Bull. 1990 Jun;16(1):42-5 [2400389.001]
  • [Cites] J Comput Assist Tomogr. 1988 Jan-Feb;12(1):143-6 [3335654.001]
  • [Cites] Skeletal Radiol. 1985;13(2):134-46 [3975659.001]
  • [Cites] Am J Clin Pathol. 1981 Mar;75(3):410-5 [7211762.001]
  • [Cites] Br J Neurosurg. 1993;7(6):683-6 [8161432.001]
  • [Cites] Ear Nose Throat J. 1993 Apr;72(4):277-9 [8486106.001]
  • [Cites] Cancer Lett. 1996 Jun 5;103(2):177-82 [8635155.001]
  • [Cites] Br J Neurosurg. 1998 Apr;12(2):165-9 [11013673.001]
  • [Cites] J Laryngol Otol. 2001 Jan;115(1):74-6 [11233634.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Dec;125(6):665-7 [11743477.001]
  • [Cites] Neurochirurgie. 2002 Feb;48(1):25-9 [11972147.001]
  • [Cites] Head Neck. 2003 Feb;25(2):168-72 [12509800.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 2002 Dec;119(6):363-8 [12527847.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2002 Aug;10(3):467-93 [12530230.001]
  • [Cites] Dentomaxillofac Radiol. 2003 Sep;32(5):343-6 [14709612.001]
  • [Cites] J Laryngol Otol. 1990 Jul;104(7):570-3 [2384715.001]
  • (PMID = 23120451.001).
  • [ISSN] 2231-3796
  • [Journal-full-title] Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
  • [ISO-abbreviation] Indian J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3452126
  • [Keywords] NOTNLM ; Ewing’s sarcoma / Paranasal sinus
  •  go-up   go-down


3. Takeda M, Yamaguchi S, Eguchi K, Kajiume T, Nishimura S, Kobayashi M, Kurisu K: Spinal epidural granulocytic sarcoma in a child precedent to clinical manifestation of acute myeloid lymphoma: case report. Neurol Med Chir (Tokyo); 2009 May;49(5):221-4
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal epidural granulocytic sarcoma in a child precedent to clinical manifestation of acute myeloid lymphoma: case report.
  • A 13-year-old boy presented with an epidural thoracic granulocytic sarcoma manifesting as rapidly progressive paraplegia preceding clinical manifestation of acute myeloid leukemia (AML).
  • The initial histological diagnosis was malignant lymphoma.
  • The correct diagnosis of epidural granulocytic sarcoma and AML was established based on cell-surface markers and a chromosomal study of the bone marrow cells.
  • A combination of chemotherapy and bone marrow transfusion achieved complete remission of leukemia.
  • Granulocytic sarcoma should be considered in the differential diagnosis of an epidural mass in pediatric patients with or without acute leukemia.
  • Immediate diagnosis and appropriate treatment are recommended to prevent leukemic transformation.
  • [MeSH-major] Epidural Neoplasms / surgery. Leukemia, Myeloid, Acute / diagnosis. Sarcoma, Myeloid / surgery. Spinal Neoplasms / surgery
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Combined Modality Therapy. Exophthalmos / etiology. Humans. Laminectomy. Magnetic Resonance Imaging. Male. Methylprednisolone / therapeutic use. Orbit / pathology. Paraplegia / etiology. Remission Induction. Temporal Lobe / pathology. Thoracic Vertebrae / surgery

  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19465795.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


Advertisement
4. Alkatan HM, Maktabi A: Malignant fibrous histiocytoma in a patient with history of treated retinoblastoma. Saudi J Ophthalmol; 2010 Jan;24(1):23-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histopathology showed a moderately differentiated tumor with vitreous seeding and he received chemotherapy in addition to radiotherapy to his right eye.
  • He presented 20 years later with a right orbital tumor, frozen globe and proptosis.
  • The excisional biopsy of his orbital mass revealed a spindle cell sarcoma with features of malignant fibrous histiocytoma.
  • His clinical and radiological findings are presented together with the histopathologic features of his orbital tumor and brief review of secondary tumors in retinoblastoma patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23960869.001).
  • [ISSN] 1319-4534
  • [Journal-full-title] Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
  • [ISO-abbreviation] Saudi J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Other-IDs] NLM/ PMC3729799
  • [Keywords] NOTNLM ; Orbit / Retinoblastoma / Second tumors
  •  go-up   go-down


5. Verma V, Shen D, Sieving PC, Chan CC: The role of infectious agents in the etiology of ocular adnexal neoplasia. Surv Ophthalmol; 2008 Jul-Aug;53(4):312-31
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Given the fact that infectious agents contribute to around 18% of human cancers worldwide, it would seem prudent to explore their role in neoplasms of the ocular adnexa: primary malignancies of the conjunctiva, lacrimal glands, eyelids, and orbit.
  • By elucidating the mechanisms by which infectious agents contribute to oncogenesis, the management, treatment, and prevention of these neoplasms may one day parallel what is already in place for cancers such as cervical cancer, hepatocellular carcinoma, gastric mucosa-associated lymphoid tissue lymphoma and gastric adenocarcinoma.
  • Antibiotic treatment and vaccines against infectious agents may herald a future with a curtailed role for traditional therapies of surgery, radiation, and chemotherapy.
  • This review discusses the pathogenetic role of several microorganisms in different ocular adnexal malignancies, including human papilloma virus in conjunctival papilloma and squamous cell carcinoma, human immunodeficiency virus in conjunctival squamous carcinoma, Kaposi sarcoma-associated herpes virus or human herpes simplex virus-8 (KSHV/HHV-8) in conjunctival Kaposi sarcoma, Helicobacter pylori (H. pylori,), Chlamydia, and hepatitis C virus in ocular adnexal mucosa-associated lymphoid tissue lymphomas.
  • [MeSH-minor] Alphapapillomavirus / isolation & purification. Alphapapillomavirus / physiology. Carcinoma, Squamous Cell / virology. Chlamydophila psittaci / isolation & purification. Chlamydophila psittaci / physiology. Conjunctival Neoplasms / microbiology. Conjunctival Neoplasms / virology. Eyelid Neoplasms / microbiology. Eyelid Neoplasms / virology. HIV-1 / isolation & purification. HIV-1 / physiology. Helicobacter pylori / isolation & purification. Helicobacter pylori / physiology. Hepacivirus / isolation & purification. Hepacivirus / physiology. Herpesvirus 8, Human / isolation & purification. Herpesvirus 8, Human / physiology. Humans. Lacrimal Apparatus Diseases / microbiology. Lacrimal Apparatus Diseases / virology. Lymphoma, B-Cell, Marginal Zone / virology. Orbital Neoplasms / microbiology. Orbital Neoplasms / virology. Sarcoma, Kaposi / virology

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Ophthalmol Scand. 2000 Dec;78(6):663-6 [11167228.001]
  • [Cites] J Virol. 2001 Feb;75(4):1857-63 [11160684.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1218-23 [11158620.001]
  • [Cites] Ophthalmology. 2001 Mar;108(3):559-62 [11237911.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] AIDS. 2001 Mar 30;15(5):629-33 [11317001.001]
  • [Cites] Ophthalmology. 2001 May;108(5):979-84 [11320031.001]
  • [Cites] Br J Cancer. 2002 Jul 29;87(3):301-8 [12177799.001]
  • [Cites] Cornea. 2002 Nov;21(8):838-9 [12410049.001]
  • [Cites] Leuk Lymphoma. 2002 Oct;43(10):1975-7 [12481895.001]
  • [Cites] Cornea. 2003 Jan;22(1):1-4 [12502938.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):489-90 [12571255.001]
  • [Cites] Arch Ophthalmol. 2003 Feb;121(2):280-2 [12583801.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):159-69 [12584163.001]
  • [Cites] Ophthalmologe. 2003 Feb;100(2):142-4 [12589459.001]
  • [Cites] Cornea. 2003 Mar;22(2):135-7 [12605048.001]
  • [Cites] Acta Ophthalmol Scand. 2003 Apr;81(2):193-6 [12752062.001]
  • [Cites] Oncogene. 2003 May 29;22(22):3371-85 [12776188.001]
  • [Cites] Arch Soc Esp Oftalmol. 2003 May;78(5):265-71 [12789630.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):57-65 [12807947.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):673-96, v [12852650.001]
  • [Cites] Acta Ophthalmol Scand. 2003 Aug;81(4):411-3 [12859274.001]
  • [Cites] Arch Ophthalmol. 2003 Jul;121(7):1052-3 [12860816.001]
  • [Cites] J Med Microbiol. 2003 Aug;52(Pt 8):721-6 [12867569.001]
  • [Cites] Lancet. 2003 Jul 26;362(9380):305-15 [12892963.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):865-71 [12910532.001]
  • [Cites] Ann Oncol. 2003 Sep;14(9):1341-5 [12954572.001]
  • [Cites] Cent Afr J Med. 2003 Jan-Feb;49(1-2):1-4 [14562592.001]
  • [Cites] Ophthalmology. 2004 Sep;111(9):1747-54 [15350332.001]
  • [Cites] Histol Histopathol. 2004 Oct;19(4):1219-26 [15375765.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] N Engl J Med. 1978 Nov 30;299(22):1215-20 [309554.001]
  • [Cites] Am J Ophthalmol. 1982 Apr;93(4):393-402 [6280503.001]
  • [Cites] Ann Ophthalmol. 1982 May;14(5):497-9 [7114684.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1410-6 [6193858.001]
  • [Cites] Am J Ophthalmol. 1983 Nov;96(5):670-4 [6314814.001]
  • [Cites] Ophthalmology. 1984 Sep;91(9):1092-9 [6093020.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1985;223(3):164-7 [2993107.001]
  • [Cites] Anticancer Res. 1985 Sep-Oct;5(5):485-98 [3904595.001]
  • [Cites] Ophthalmology. 1986 Feb;93(2):176-83 [3951824.001]
  • [Cites] Arch Ophthalmol. 1986 Dec;104(12):1801-5 [3024607.001]
  • [Cites] Arch Ophthalmol. 1986 Dec;104(12):1814-5 [3024608.001]
  • [Cites] Am J Ophthalmol. 1987 Mar 15;103(3 Pt 1):294-301 [3030111.001]
  • [Cites] J Natl Cancer Inst. 1987 Oct;79(4):671-7 [2821311.001]
  • [Cites] Hum Pathol. 1987 Nov;18(11):1115-9 [2824322.001]
  • [Cites] Hum Pathol. 1988 Nov;19(11):1315-26 [3141260.001]
  • [Cites] N Engl J Med. 1989 Jun 1;320(22):1442-6 [2541337.001]
  • [Cites] Lancet. 1990 Jan 20;335(8682):123-8 [1967430.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] Nat Med. 1995 Dec;1(12):1274-8 [7489408.001]
  • [Cites] CA Cancer J Clin. 1996 Jan-Feb;46(1):5-27 [8548526.001]
  • [Cites] J Clin Pathol. 1995 Dec;48(12):1106-10 [8567996.001]
  • [Cites] Ophthalmology. 1996 Apr;103(4):631-5 [8618763.001]
  • [Cites] Lancet. 1996 May 25;347(9013):1450-1 [8676629.001]
  • [Cites] Am J Pathol. 1996 Jun;148(6):2009-16 [8669485.001]
  • [Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]
  • [Cites] Br J Ophthalmol. 1999 Jun;83(6):742-7 [10340987.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 20;91(20):1725-33 [10528022.001]
  • [Cites] Sex Transm Infect. 1999 Oct;75(5):317-9 [10616355.001]
  • [Cites] AIDS. 1999 Dec 24;13(18):2583-8 [10630528.001]
  • [Cites] J Clin Pathol. 1999 Aug;52(8):569-73 [10645225.001]
  • [Cites] Br J Ophthalmol. 2000 Mar;84(3):268-72 [10684836.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2000 May;41(6):1270-9 [10798640.001]
  • [Cites] J Immunol. 2000 May 15;164(10):5522-9 [10799921.001]
  • [Cites] Nat Med. 2000 May;6(5):536-42 [10802709.001]
  • [Cites] J Biomed Sci. 2000 Sep-Oct;7(5):341-56 [10971133.001]
  • [Cites] J Med Virol. 2000 Oct;62(2):251-8 [11002256.001]
  • [Cites] Arch Ophthalmol. 1997 Nov;115(11):1464-6 [9366682.001]
  • [Cites] Gastroenterology. 1997 Dec;113(6):1848-57 [9394724.001]
  • [Cites] Gastroenterology. 1997 Dec;113(6 Suppl):S61-4 [9394762.001]
  • [Cites] Ophthalmology. 1998 Jan;105(1):185-90 [9442797.001]
  • [Cites] N Engl J Med. 1998 Feb 12;338(7):423-8 [9459645.001]
  • [Cites] Am J Respir Crit Care Med. 1998 Feb;157(2):458-63 [9476858.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2290-5 [9482878.001]
  • [Cites] Br J Ophthalmol. 1997 Nov;81(11):1019-20 [9505833.001]
  • [Cites] Annu Rev Med. 1998;49:289-99 [9509264.001]
  • [Cites] N Engl J Med. 1998 Apr 2;338(14):948-54 [9521982.001]
  • [Cites] Sex Transm Infect. 1998 Feb;74(1):32-4 [9634298.001]
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):65-71 [9709306.001]
  • [Cites] Bull Soc Belge Ophtalmol. 1998;268:135-41 [9810095.001]
  • [Cites] AIDS. 1998 Oct 22;12(15):2067-72 [9814876.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1999 Mar;40(3):555-62 [10067957.001]
  • [Cites] Gastroenterology. 1999 Apr;116(4):823-30 [10092304.001]
  • [Cites] Ophthalmology. 1999 Apr;106(4):757-60 [10201599.001]
  • [Cites] Br J Ophthalmol. 1999 Jan;83(1):98-103 [10209445.001]
  • [Cites] J Reprod Immunol. 1998 Dec;41(1-2):149-60 [10213307.001]
  • [Cites] J Vet Intern Med. 1999 May-Jun;13(3):153-62 [10357102.001]
  • [Cites] Cornea. 1999 Jul;18(4):495-7 [10422866.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] BMJ. 1999 Aug 21;319(7208):505-8 [10454408.001]
  • [Cites] Cornea. 2001 May;20(4):427-9 [11333335.001]
  • [Cites] Br J Ophthalmol. 2001 Jul;85(7):785-7 [11423448.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1251-69 [11423257.001]
  • [Cites] Mod Pathol. 2001 Jul;14(7):641-9 [11454995.001]
  • [Cites] Dermatology. 2001;203(1):19-23 [11549794.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2001 Oct;42(11):2450-7 [11581182.001]
  • [Cites] Lancet. 2001 Sep 22;358(9286):958-65 [11583749.001]
  • [Cites] Ann N Y Acad Sci. 2001 Sep;941:69-85 [11594584.001]
  • [Cites] JAMA. 2002 Jan 9;287(2):221-5 [11779265.001]
  • [Cites] Curr Opin Immunol. 2002 Feb;14(1):111-6 [11790540.001]
  • [Cites] Br J Ophthalmol. 2002 Feb;86(2):168-73 [11815342.001]
  • [Cites] Arch Ophthalmol. 2002 Feb;120(2):202-4 [11831924.001]
  • [Cites] Oncogene. 2002 Feb 14;21(8):1251-62 [11850845.001]
  • [Cites] Can J Ophthalmol. 2002 Feb;37(1):14-9; discussion 19-20 [11865953.001]
  • [Cites] Ophthalmology. 2002 Mar;109(3):542-7 [11874759.001]
  • [Cites] Adv Cancer Res. 2002;84:231-76 [11883529.001]
  • [Cites] Am J Clin Pathol. 2002 Mar;117(3):429-36 [11888082.001]
  • [Cites] J Clin Pathol. 2002 Apr;55(4):244-65 [11919208.001]
  • [Cites] Am J Ophthalmol. 2002 May;133(5):601-6 [11992855.001]
  • [Cites] Oncogene. 2002 Jun 6;21(25):3949-60 [12037677.001]
  • [Cites] Am J Ophthalmol. 2002 Aug;134(2):268-70 [12140037.001]
  • [Cites] J Virol. 2005 Dec;79(24):15027-37 [16306573.001]
  • [Cites] Ophthalmologe. 2005 Dec;102(12):1204-6 [15657692.001]
  • [Cites] Ann Oncol. 2006 Jan;17(1):135-40 [16236754.001]
  • [Cites] J Virol. 2006 Jan;80(2):697-709 [16378973.001]
  • [Cites] Blood. 2006 Jan 15;107(2):467-72 [16166588.001]
  • [Cites] Ophthalmologe. 2003 Oct;100(10):808-14 [14618353.001]
  • [Cites] Gut. 2004 Jan;53(1):34-7 [14684573.001]
  • [Cites] J Pathol. 2004 Jan;202(1):23-33 [14694518.001]
  • [Cites] Oral Oncol. 2004 Feb;40(2):120-30 [14693234.001]
  • [Cites] Curr Hematol Rep. 2004 Jan;3(1):11-6 [14695844.001]
  • [Cites] Surv Ophthalmol. 2004 Jan-Feb;49(1):3-24 [14711437.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1723-32 [14724825.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] J Virol. 2004 Apr;78(8):4063-73 [15047823.001]
  • [Cites] J Clin Microbiol. 2004 Apr;42(4):1648-51 [15071020.001]
  • [Cites] J Natl Cancer Inst. 2004 Apr 21;96(8):586-94 [15100336.001]
  • [Cites] Ophthalmology. 2004 Jun;111(6):1233-7 [15177977.001]
  • [Cites] Croat Med J. 2004 Jun;45(3):328-32 [15185428.001]
  • [Cites] Eur J Haematol. 2004 Oct;73(4):258-62 [15347312.001]
  • [Cites] Klin Oczna. 2005;107(7-9):475-8 [16417001.001]
  • [Cites] Br J Haematol. 2006 Mar;132(5):651-2 [16445841.001]
  • [Cites] Jpn J Ophthalmol. 2006 Jan-Feb;50(1):7-11 [16453181.001]
  • [Cites] Ann Oncol. 2006 Mar;17(3):484-7 [16500916.001]
  • [Cites] Int J Surg Pathol. 2006 Jan;14(1):85-8 [16501843.001]
  • [Cites] Hematol Oncol. 2006 Mar;24(1):33-7 [16385613.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):365-6 [16507837.001]
  • [Cites] Virchows Arch. 2006 Mar;448(3):301-5 [16328355.001]
  • [Cites] Leuk Res. 2006 May;30(5):547-51 [16246419.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3030-44 [16404738.001]
  • [Cites] J Infect Dis. 2006 May 1;193(9):1250-7 [16586362.001]
  • [Cites] Virchows Arch. 2006 Apr;448(4):506-16 [16323006.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3034-44 [16397126.001]
  • [Cites] Am J Gastroenterol. 2006 Apr;101(4):714-20 [16635219.001]
  • [Cites] Ann Oncol. 2006 May;17(5):769-72 [16524978.001]
  • [Cites] Cornea. 2006 May;25(4):490-2 [16670494.001]
  • [Cites] J Mol Histol. 2005 Sep;36(6-7):401-12 [16402152.001]
  • [Cites] Eur J Ophthalmol. 2006 May-Jun;16(3):473-7 [16761254.001]
  • [Cites] Am J Ophthalmol. 2006 Jun;141(6):1162-3 [16765702.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9220-5 [16751281.001]
  • [Cites] Br J Ophthalmol. 2006 Jul;90(7):819-22 [16672325.001]
  • [Cites] J Pathol. 2006 Jul;209(3):344-51 [16583361.001]
  • [Cites] Ann Oncol. 2006 Jun;17 Suppl 8:viii15-viii23 [16801335.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1992 Jan;33(1):184-9 [1309728.001]
  • [Cites] Br J Ophthalmol. 1992 Jan;76(1):47-8 [1739692.001]
  • [Cites] Lancet. 1992 Mar 14;339(8794):632-5 [1347337.001]
  • [Cites] J Virol. 1992 Apr;66(4):2125-34 [1312623.001]
  • [Cites] Acta Ophthalmol (Copenh). 1992 Apr;70(2):248-54 [1319099.001]
  • [Cites] Adv Exp Med Biol. 1992;321:45-9; discussion 51 [1333167.001]
  • [Cites] Ophthalmology. 1993 Apr;100(4):569-73 [8386822.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1267-71 [8145781.001]
  • [Cites] Cancer. 1994 May 1;73(9):2395-9 [8168043.001]
  • [Cites] Radiother Oncol. 1994 Mar;30(3):263-6 [7516086.001]
  • [Cites] Am J Ophthalmol. 1994 Oct 15;118(4):463-7 [7943124.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Dec 1;30(5):1207-11 [7525519.001]
  • [Cites] J Pathol. 1994 Sep;174(1):33-7 [7965401.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Lancet. 1995 Mar 18;345(8951):695-6 [7885126.001]
  • [Cites] Lancet. 1995 Mar 25;345(8952):761-2 [7891488.001]
  • [Cites] Br J Ophthalmol. 1995 Apr;79(4):392-3 [7742294.001]
  • [Cites] Lancet. 1995 Jun 24;345(8965):1591-4 [7783535.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 7;87(11):796-802 [7791229.001]
  • [Cites] Arch Ophthalmol. 1995 Aug;113(8):978 [7639671.001]
  • [Cites] Nat Med. 1995 Jul;1(7):707-8 [7585156.001]
  • [Cites] Cancer Lett. 2006 Jul 28;239(1):98-102 [16143449.001]
  • [Cites] J Natl Cancer Inst. 2006 Jul 5;98(13):936-9 [16818858.001]
  • [Cites] Mod Pathol. 2006 Aug;19(8):1055-67 [16648871.001]
  • [Cites] East Afr Med J. 2006 May;83(5):267-70 [16866221.001]
  • [Cites] Ophthalmic Epidemiol. 2006 Aug;13(4):275-9 [16877286.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):479-86 [16894296.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4491-8 [16899594.001]
  • [Cites] Leuk Res. 2006 Oct;30(10):1305-7 [16420962.001]
  • [Cites] Viral Immunol. 2006 Summer;19(3):468-80 [16987065.001]
  • [Cites] J Natl Cancer Inst. 2006 Oct 4;98(19):1375-82 [17018784.001]
  • [Cites] J Med Microbiol. 2006 Nov;55(Pt 11):1571-5 [17030918.001]
  • [Cites] Ann Oncol. 2006 Nov;17(11):1721-2 [16760269.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11120-4 [17145854.001]
  • [Cites] Rev Med Interne. 2007 Jan;28(1):22-7 [17070619.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):170-84 [17255761.001]
  • [Cites] Clin Pharmacol Ther. 2007 Feb;81(2):259-64 [17259949.001]
  • [Cites] Ann Oncol. 2007 Feb;18(2):400-1; author reply 401-3 [17065589.001]
  • [Cites] Leuk Lymphoma. 2007 Jan;48(1):104-8 [17325853.001]
  • [Cites] J Acquir Immune Defic Syndr. 2007 Mar 1;44(3):351-5 [17195763.001]
  • [Cites] Trans Am Ophthalmol Soc. 2006;104:62-70 [17471326.001]
  • [Cites] Br J Ophthalmol. 2007 Aug;91(8):1014-5 [17166894.001]
  • [Cites] Cancer Treat Res. 2007;133:185-213 [17672042.001]
  • [Cites] Leuk Res. 2007 Oct;31(10):1450-2 [17257672.001]
  • [Cites] Ophthalmology. 2007 Jan;114(1):182-6 [17198854.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] Ann Dermatol Venereol. 1996;123(2):90-2 [8761758.001]
  • [Cites] Infect Immun. 1996 Nov;64(11):4872-5 [8890256.001]
  • [Cites] Nippon Ganka Gakkai Zasshi. 1996 Mar;100(3):246-52 [8900592.001]
  • [Cites] CA Cancer J Clin. 1997 Jan-Feb;47(1):5-27 [8996076.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Feb;83(2):259-64 [9117759.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Feb;6(2):73-7 [9037556.001]
  • [Cites] Ophthalmology. 1995 Dec;102(12):1994-2006 [9098307.001]
  • [Cites] Am J Ophthalmol. 1997 Apr;123(4):551-2 [9124255.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Jun;6(6):387-400 [9184771.001]
  • [Cites] Br J Ophthalmol. 1997 Apr;81(4):308-13 [9215061.001]
  • [Cites] Blood. 1997 Jul 15;90(2):776-82 [9226178.001]
  • [Cites] Aust N Z J Ophthalmol. 1997 Aug;25(3):211-5 [9296295.001]
  • [Cites] Clin Microbiol Rev. 1997 Oct;10(4):720-41 [9336670.001]
  • [Cites] J Clin Microbiol. 1999 Oct;37(10):3316-22 [10488198.001]
  • [Cites] Rev Esp Enferm Dig. 1999 Aug;91(8):541-8 [10491486.001]
  • [Cites] Am J Ophthalmol. 1999 Sep;128(3):362-4 [10511035.001]
  • [Cites] Am J Ophthalmol. 1950 Aug;33(8):1203-19 [15432557.001]
  • [Cites] Am J Clin Pathol. 2004 Dec;122(6):938-43 [15539387.001]
  • [Cites] Ann Hematol. 2005 Jan;84(1):13-8 [15309523.001]
  • [Cites] Ophthalmologe. 2004 Oct;101(10):1011-6 [15185119.001]
  • [Cites] Cytokine. 2005 Feb 21;29(4):141-52 [15652446.001]
  • [Cites] Retina. 2005 Jan;25(1):94-8 [15655452.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Am J Gastroenterol. 2005 Feb;100(2):290-4 [15667484.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):939-47 [15705894.001]
  • [Cites] Acta Dermatovenerol Croat. 2005;13(1):22-7 [15788143.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):773-8 [15824142.001]
  • [Cites] J Virol. 2005 Jul;79(13):8079-89 [15956553.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5067-73 [15968003.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2005 Jul;21(4):314-5 [16052151.001]
  • [Cites] Mol Carcinog. 2005 Oct;44(2):77-82 [16075467.001]
  • [Cites] Nat Rev Immunol. 2005 Oct;5(10):749-59 [16175180.001]
  • [Cites] Nippon Ganka Gakkai Zasshi. 2005 Sep;109(9):573-9 [16218435.001]
  • [Cites] Am J Ophthalmol. 2005 Oct;140(4):729-30 [16226528.001]
  • [Cites] Arch Dermatol. 2005 Nov;141(11):1429-34 [16301390.001]
  • (PMID = 18572051.001).
  • [ISSN] 0039-6257
  • [Journal-full-title] Survey of ophthalmology
  • [ISO-abbreviation] Surv Ophthalmol
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 EY000222-22
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Number-of-references] 248
  • [Other-IDs] NLM/ NIHMS58178; NLM/ PMC2507724
  •  go-up   go-down


6. Raney B, Stoner J, Anderson J, Andrassy R, Arndt C, Brown K, Crist W, Maurer H, Qualman S, Wharam M, Wiener E, Meyer W, Hayes-Jordan A, Soft-Tissue Sarcoma Committee of the Children's Oncology Group: Impact of tumor viability at second-look procedures performed before completing treatment on the Intergroup Rhabdomyosarcoma Study Group protocol IRS-IV, 1991-1997: a report from the children's oncology group. J Pediatr Surg; 2010 Nov;45(11):2160-8
MedlinePlus Health Information. consumer health - Diagnostic Imaging.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of tumor viability at second-look procedures performed before completing treatment on the Intergroup Rhabdomyosarcoma Study Group protocol IRS-IV, 1991-1997: a report from the children's oncology group.
  • PURPOSES: The aims of the study were to compare results of clinical/radiographic studies before second-look procedures (SLP) with SLP specimens from patients with gross residual sarcoma at diagnosis and to relate tumor viability to outcome.
  • PATIENTS: Seventy-three patients underwent SLP before completing chemotherapy, with (n = 59) or without (n = 14) radiotherapy.
  • Tumor sites were bladder/prostate (n = 27), head/orbit/parameningeal (n = 22), extremity/trunk (n = 14), and retroperitoneum/pelvis (n = 10).
  • Five-year survival was 78% to 79% among 73 patients with and 333 patients without SLP during treatment.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Inc.
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Sep;28(9):563-7 [17006261.001]
  • [Cites] J Clin Oncol. 2009 Aug 1;27(22):3705-11 [19470937.001]
  • [Cites] Pediatr Blood Cancer. 2008 Nov;51(5):593-7 [18668515.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] Med Pediatr Oncol. 1994;22(1):22-6 [8232076.001]
  • [Cites] Cancer. 1993 Mar 1;71(5):1904-22 [8448756.001]
  • [Cites] Acta Oncol. 1989;28(1):67-72 [2706134.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):209-20 [3275486.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] J Urol. 2004 Jun;171(6 Pt 1):2396-403 [15126860.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1974-80 [12673726.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):718-28 [11597814.001]
  • (PMID = 21034938.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-98543; United States / NCI NIH HHS / CA / U10 CA072989; United States / NCI NIH HHS / CA / U10 CA029511; United States / NCI NIH HHS / CA / CA-24507; United States / NCI NIH HHS / CA / CA-72989; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA-29511; United States / NCI NIH HHS / CA / U10 CA024507
  • [Publication-type] Clinical Trial, Phase IV; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS265975; NLM/ PMC3128803
  •  go-up   go-down


7. Pang NK, Bartley GB, Giannini C: Primary Ewing sarcoma of the orbit in an adult. Ophthal Plast Reconstr Surg; 2007 Mar-Apr;23(2):153-4
Genetic Alliance. consumer health - Ewing's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary Ewing sarcoma of the orbit in an adult.
  • A 42-year-old man presented with visual field loss in the right eye and unintentional weight loss associated with a right orbital mass.
  • Surgical resection and biopsy revealed a diagnosis of Ewing sarcoma, and systemic evaluation showed no metastasis.
  • Subsequent chemotherapy and radiation resulted in tumor resolution without recurrence for 3.5 years.
  • [MeSH-major] Orbital Neoplasms / pathology. Sarcoma, Ewing / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17413636.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Wilson DJ, Dailey RA, Griffeth MT, Newton CJ: Primary Ewing sarcoma of the orbit. Ophthal Plast Reconstr Surg; 2001 Jul;17(4):300-3
Genetic Alliance. consumer health - Ewing's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary Ewing sarcoma of the orbit.
  • PURPOSE: To report the clinicopathologic features of a 17-year-old patient with primary Ewing sarcoma of the orbit.
  • METHODS: The patient was evaluated clinically before surgery with computed tomography scans of the orbit.
  • After surgery, the patient was staged with computed tomography scans and bone scan and was treated with systemic chemotherapy and radiation therapy to the orbit.
  • The orbital biopsy was evaluated with conventional light microscopy and immunohistochemistry.
  • Computed tomography scans disclosed a mass involving the superior orbit, anterior cranial fossa, and temporal fossa.
  • Computed tomography scan, bone scan, and blood chemistries revealed no other site of involvement.
  • After treatment, the clinical symptoms and signs resolved, and there has been no evidence of residual orbital tumor or metastasis.
  • CONCLUSIONS: Primary Ewing sarcoma of the orbit should be considered in the differential diagnosis of children or young adults with proptosis, diplopia, or periorbital swelling.
  • Immunohistochemistry is essential to distinguish Ewing sarcoma from other small round cell tumors.
  • [MeSH-major] Orbital Neoplasms / pathology. Sarcoma, Ewing / pathology
  • [MeSH-minor] Adolescent. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11476182.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


9. Dutton JJ, Rose JG Jr, DeBacker CM, Gayre G: Orbital Ewing's sarcoma of the orbit. Ophthal Plast Reconstr Surg; 2000 Jul;16(4):292-300
Genetic Alliance. consumer health - Ewing's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital Ewing's sarcoma of the orbit.
  • PURPOSE: Ewing's tumor is a primary tumor of bone in childhood that only rarely involves the orbit.
  • This tumor may be confused with other small round cell malignancies of childhood, and immunohistochemical studies are essential in making the diagnosis.
  • METHODS: We present two cases of Ewing's tumor of the orbit.
  • RESULTS: In most cases with orbital involvement, ophthalmic symptoms consist of proptosis, pain, and occasionally visual loss and motility restriction.
  • The diagnosis is typically unsuspected before histologic evaluation.
  • Electron microscopic and immunohistochemical analyses are essential in making the diagnosis and are necessary for all such small round cell tumors.
  • CONCLUSIONS: Ewing's sarcoma is a rare orbital tumor of bone mainly affecting children.
  • Local treatment relying on surgical extirpation and radiotherapy alone has proven inadequate, with 5-year survival rates of <10%.
  • The addition of chemotherapy has improved survival rates significantly to approximately 50%.
  • [MeSH-major] Orbital Neoplasms / diagnosis. Sarcoma, Ewing / diagnosis
  • [MeSH-minor] Biopsy. Child. Child, Preschool. Diagnosis, Differential. Fatal Outcome. Humans. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10923978.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


10. Kano T, Sasaki A, Tomizawa S, Shibasaki T, Tamura M, Ohye C: Primary Ewing's sarcoma of the orbit: case report. Brain Tumor Pathol; 2009;26(2):95-100
Hazardous Substances Data Bank. HEMATOXYLIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary Ewing's sarcoma of the orbit: case report.
  • A 22-year-old man presented with tenderness and swelling of the left lateral part of the orbit.
  • Computed tomography revealed a left intraorbital mass measuring 3 cm x 3 cm involving the left lateral wall of the orbit and the greater wing of the left sphenoid bone.
  • During surgery, the tumor was seen to arise from the lateral wall of the orbit and infiltrate into the left temporal muscle.
  • Following the surgery, the patient was administered radiation therapy for the whole cranium and chemotherapy for the residual tumors.
  • Based on these results, the tumor was diagnosed to be primary Ewing's sarcoma.
  • Primary orbital Ewing's sarcoma of the skull has been considered to be extremely rare, and a review of the literature was performed.
  • [MeSH-major] Neuroectodermal Tumors, Primitive, Peripheral / diagnosis. Orbital Neoplasms / diagnosis. Sarcoma, Ewing / diagnosis

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19856222.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] TDQ283MPCW / Eosine Yellowish-(YS); YKM8PY2Z55 / Hematoxylin
  •  go-up   go-down


11. Bhattacharjee K, Bhattacharjee H, Das D, Babu K, Mahesh L, Krishnakumar S, Biswas J: Chloroma of the orbit in a non-leukemic adult: A case report. Orbit; 2003 Dec;22(4):293-7
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chloroma of the orbit in a non-leukemic adult: A case report.
  • Granulocytic sarcoma has been reported as an isolated lesion in non-leukemic patients.
  • However, the majority of these subjects develop acute leukemia within a mean interval of 10.5 months from the time of diagnosis.
  • We present a case of granulocytic sarcoma of the orbit in a non-leukemic patient who was treated with chemotherapy and is doing well after a 2-year period.
  • Appropriate treatment is delayed in most cases because of a high rate of misdiagnosis.
  • [MeSH-major] Orbital Neoplasms / pathology. Sarcoma, Myeloid / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Diagnosis, Differential. Humans. Male. Mitoxantrone / administration & dosage

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14685905.001).
  • [ISSN] 0167-6830
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; BZ114NVM5P / Mitoxantrone; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


12. Lakhkar BN, Banavali S, Philip P: Orbital granulocytic sarcoma in acute myelogenous leukemia. Indian J Pediatr; 2000 Mar;67(3):234-5
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital granulocytic sarcoma in acute myelogenous leukemia.
  • CT scan showed bilateral extra-conal homogeneously enhancing soft tissue masses, larger on the left side.
  • A possibility of granulocytic sarcoma of the orbit was considered.
  • Diagnosis was confirmed by peripheral smear and bone marrow aspiration.
  • Patient responded to chemotherapy.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Orbital Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1978 Apr;41(4):1606-9 [205341.001]
  • [Cites] Radiology. 1994 Mar;190(3):698-702 [8115614.001]
  • [Cites] Cancer. 1973 Apr;31(4):948-55 [4513297.001]
  • [Cites] Radiology. 1985 Apr;155(1):167-70 [3856292.001]
  • [Cites] Ophthalmologica. 1998;212(3):202-5 [9562099.001]
  • [Cites] Br Med J. 1965 Aug 14;2(5458):405-7 [20722188.001]
  • [Cites] Ophthalmology. 1985 Dec;92(12):1758-62 [3867055.001]
  • [Cites] Am J Ophthalmol. 1975 Dec;80(6):975-90 [1060381.001]
  • (PMID = 10838728.001).
  • [ISSN] 0019-5456
  • [Journal-full-title] Indian journal of pediatrics
  • [ISO-abbreviation] Indian J Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


13. Ohta K, Kondoh T, Yasuo K, Kohsaka Y, Kohmura E: Primary granulocytic sarcoma in the sphenoidal bone and orbit. Childs Nerv Syst; 2003 Sep;19(9):674-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary granulocytic sarcoma in the sphenoidal bone and orbit.
  • The tumor was partially calcified and was a round mass located in the bilateral sphenoidal bone extending into the orbit.
  • The tumor was partially removed by bilateral frontotemporal craniotomy and a diagnosis of primary granulocytic sarcoma was made from the surgical specimen.
  • Progressive deterioration of visual acuity was seen and chemotherapy started on the 11th postoperative day followed by local cranium irradiation (24 Gy).
  • DISCUSSION: Radiological diagnosis of primary intracranial granulocytic sarcoma is difficult.
  • Surgical removal may be an option for progressive neurological deterioration but chemotherapy is more important for both neurological stabilization and induction of remission.
  • [MeSH-major] Orbit / pathology. Sarcoma, Myeloid. Sphenoid Bone / pathology
  • [MeSH-minor] Brain Neoplasms / pathology. Carotid Artery, Internal / pathology. Child, Preschool. Craniotomy. Drug Therapy. Humans. Magnetic Resonance Imaging / methods. Male. Myeloid Cells / pathology. Remission Induction. Review Literature as Topic. Tomography, X-Ray Computed / methods. Visual Acuity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Pediatr Otorhinolaryngol. 1989 Dec;18(2):163-9 [2625392.001]
  • [Cites] Radiology. 1994 Mar;190(3):698-702 [8115614.001]
  • [Cites] Radiology. 1986 Jul;160(1):223-5 [3459211.001]
  • [Cites] Pediatr Radiol. 1988;18(5):369-72 [3050842.001]
  • [Cites] Br J Ophthalmol. 1997 Dec;81(12):1084-8 [9497470.001]
  • [Cites] Rev Invest Clin. 1993 Sep-Oct;45(5):473-8 [8134730.001]
  • [Cites] J Comput Assist Tomogr. 1987 Nov-Dec;11(6):938-41 [3500192.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Sep;17(8):1592-4 [8883663.001]
  • [Cites] Neurosurgery. 1997 Jun;40(6):1283-7 [9179903.001]
  • [Cites] Ann Hematol. 2000 Aug;79(8):459-62 [10985368.001]
  • [Cites] Clin Neuropathol. 1992 Jan-Feb;11(1):11-5 [1547578.001]
  • [Cites] Pediatr Radiol. 1995;25(6):488-9 [7491213.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Feb;17(2):295-310 [8938302.001]
  • [Cites] Clin Radiol. 1992 Apr;45(4):284-5 [1395391.001]
  • [Cites] Neuroradiology. 1987;29(6):590 [3481044.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Oct;23 (9):1497-9 [12372738.001]
  • [Cites] Diagn Cytopathol. 1996 Sep;15(3):237-40 [8955608.001]
  • [Cites] Childs Nerv Syst. 2002 Apr;18(3-4):153-6 [11981624.001]
  • [Cites] Haematologica. 1996 Mar-Apr;81(2):155-8 [8641646.001]
  • (PMID = 12955422.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Buono LM, Silberschmidt A, Foroozan R, Savino PJ: Metastatic synovial sarcoma to the skull base and orbit. Am J Ophthalmol; 2002 Nov;134(5):785-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic synovial sarcoma to the skull base and orbit.
  • PURPOSE: To report a case of metastatic synovial sarcoma to the parasellar area and orbit.
  • METHODS: A 43-year-old woman with a history of a right forearm synovial sarcoma treated with excision, radiation, and chemotherapy 16 months previously presented with blurred vision of the right eye, pain with eye movement, epistaxis, and a right superior division cranial nerve III palsy.
  • Magnetic resonance imaging showed a right parasellar and right orbital apex mass.
  • RESULTS: Pathologic examination of the parasellar biopsy revealed metastatic synovial sarcoma.
  • CONCLUSIONS: Metastatic synovial sarcoma should be added to the differential diagnosis of parasellar and orbital tumors.
  • [MeSH-major] Orbital Neoplasms / secondary. Sarcoma, Synovial / secondary. Skull Base Neoplasms / secondary. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Forearm. Humans. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12429268.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Pinarli FG, Oğuz A, Karadeniz C, Uluoğlu O, Akyürek N: Second primary myogenic sarcoma in a patient with bilateral retinoblastoma. Pediatr Hematol Oncol; 2004 Sep;21(6):545-50
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second primary myogenic sarcoma in a patient with bilateral retinoblastoma.
  • The authors report a patient with bilateral retinoblastoma who developed a myogenic sarcoma of the orbit after 5.5 years of diagnosis.
  • The short latency period may be explained by tumor histology with the contribution of radiotherapy and chemotherapy.
  • The prognosis of second tumors is poor despite aggressive treatment.

  • Genetic Alliance. consumer health - Retinoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15552818.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Porto L, Kieslich M, Schwabe D, Zanella FE, Lanfermann H: Granulocytic sarcoma in children. Neuroradiology; 2004 May;46(5):374-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma in children.
  • We report three children with leukaemia (two acute myeloid and one acute lymphoblastic) and granulocytic sarcoma in the skull, orbit and sinuses.
  • Although involvement by granulocytic sarcoma, with or without acute myeloid leukaemia, is described, an association with acute lymphoblastic leukaemia is rare.
  • Recognition of this rare entity is important, because early aggressive chemotherapy can bring about regression of the tumour and improve survival.
  • [MeSH-major] Orbital Neoplasms / pathology. Paranasal Sinus Neoplasms / pathology. Sarcoma, Myeloid / pathology. Skull Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Springer-Verlag
  • [Cites] Surv Ophthalmol. 1990 Jul-Aug;35(1):1-24 [2204127.001]
  • [Cites] Blood. 1980 Jul;56(1):104-8 [6155960.001]
  • [Cites] Arch Ophthalmol. 2001 Mar;119(3):443-6 [11231781.001]
  • [Cites] Comput Radiol. 1986 Jul-Aug;10 (4):175-8 [3466769.001]
  • [Cites] Am J Ophthalmol. 1967 Apr;63(4):727-32 [6022245.001]
  • [Cites] Ann Hematol. 2000 Aug;79(8):459-62 [10985368.001]
  • [Cites] Surg Neurol. 1982 Jan;17 (1):47-51 [6951309.001]
  • (PMID = 15098141.001).
  • [ISSN] 0028-3940
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Font RL, Ray R, Mazow ML, Del Valle M: Mesenchymal chondrosarcoma of the orbit: a unique radiologic-pathologic correlation. Ophthal Plast Reconstr Surg; 2009 May-Jun;25(3):219-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesenchymal chondrosarcoma of the orbit: a unique radiologic-pathologic correlation.
  • PURPOSE: To report a unique radiologic-histopathologic correlation of mesenchymal chondrosarcoma of the orbit in a 24-year-old Asian woman.
  • CT showed a left orbital mass depicting a central radiolucent, nonenhancing component, and a denser peripheral enhancing portion.
  • Histopathologic examination of the orbital mass showed a biphasic pattern of a mesenchymal chondrosarcoma exhibiting features of a high-grade sarcoma with hemangiopericytoma pattern that corresponds to the radiopaque portion of the mass and areas of chondrosarcoma that correlated with the radiolucent component of the tumor.
  • The patient underwent exenteration of the left orbit followed by radiotherapy and chemotherapy.
  • The authors believe that recognizing the different radiologic features of the orbital tumor can help clinicians in establishing the correct preoperative diagnosis of this potentially lethal neoplasm.
  • [MeSH-major] Chondrosarcoma, Mesenchymal / pathology. Chondrosarcoma, Mesenchymal / radiography. Orbital Neoplasms / pathology. Orbital Neoplasms / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Asian Continental Ancestry Group. Chemotherapy, Adjuvant. Exophthalmos / etiology. Exophthalmos / radiography. Female. Follow-Up Studies. Humans. Orbit Evisceration. Radiotherapy, Adjuvant. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19454935.001).
  • [ISSN] 1537-2677
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


18. Collaço L, Gonçalves M, Gomes L, Miranda R: Orbital Kaposi's sarcoma in acquired immunodeficiency syndrome. Eur J Ophthalmol; 2000 Jan-Mar;10(1):88-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital Kaposi's sarcoma in acquired immunodeficiency syndrome.
  • A 28-year-old white male with AIDS-C3 staging, presented with an extensive hemorrhagic dark mass localized in the left orbit.
  • Ultrasonography and computed axial tomographic scans showed orbital involvement.
  • Orbital Kaposi's sarcoma is a rare finding and only a few cases have been reported.
  • Systemic examination revealed other lesions suggestive of disseminated mucocutaneous Kaposi's sarcoma, oral candidiasis, membranous esophagitis and granulomatous hepatitis.
  • Eyelid incisional biopsy disclosed Kaposi's sarcoma.
  • Despite intensive chemotherapy progression was aggressive with a fatal outcome.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Orbital Neoplasms / complications. Sarcoma, Kaposi / complications
  • [MeSH-minor] Adult. Candidiasis, Oral / complications. Candidiasis, Oral / diagnosis. Esophagitis / complications. Esophagitis / diagnosis. Hepatitis / complications. Hepatitis / diagnosis. Humans. Male. Tomography, X-Ray Computed


19. Mahesh L, Krishnakumar S, Subramanian N, Babu K, Biswas J: Malignant teratoma of the orbit: a clinicopathological study of a case. Orbit; 2003 Dec;22(4):305-9
Genetic Alliance. consumer health - Teratoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant teratoma of the orbit: a clinicopathological study of a case.
  • PURPOSE: To present a case of malignant sarcomatous changes in an orbital teratoma with clinicopathological correlation.
  • Computerized tomography (CT) revealed a heterogeneous retrobulbar mass in the left orbit.
  • The child was treated with chemotherapy and radiotherapy with a provisional diagnosis of sarcoma.
  • CONCLUSION: Orbital teratomas should be considered in the differential diagnosis of all neonatal orbital masses.
  • FNAB is not helpful in the diagnosis.
  • Surgical excision of the mass is recommended for a definitive diagnosis.
  • Although the prognosis of orbital teratoma is good, there is always a chance of vision loss.
  • [MeSH-major] Orbital Neoplasms / congenital. Orbital Neoplasms / pathology. Teratoma / congenital. Teratoma / pathology
  • [MeSH-minor] Combined Modality Therapy. Humans. Infant. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14685907.001).
  • [ISSN] 0167-6830
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


20. Shields JA, Shields CL, Brotman HK, Carvalho C, Perez N, Eagle RC Jr: Cancer metastatic to the orbit: the 2000 Robert M. Curts Lecture. Ophthal Plast Reconstr Surg; 2001 Sep;17(5):346-54
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer metastatic to the orbit: the 2000 Robert M. Curts Lecture.
  • PURPOSE: To report the demographics and clinical features of a large series of patients with orbital metastasis.
  • METHODS: Retrospective chart review on 100 consecutive patients and a literature review on orbital metastasis.
  • Of patients in whom a detailed history was available, there was no history of cancer at the time of presentation in 19%.
  • There were 36 male patients and 64 female patients whose mean age at diagnosis was 62 years (median 60 years, range 5 to 91 years).
  • Treatment included chemotherapy, hormone therapy, irradiation, surgical excision, or observation, depending on clinical circumstances.
  • Among patients with sufficient follow-up, 95% died of metastasis, with overall mean survival of 15 months (median 15 months; range 3 to 96 months) after orbital diagnosis.
  • CONCLUSIONS: The most common primary cancers that metastasize to the orbit are breast, prostate gland, and lung cancer.
  • [MeSH-major] Carcinoma / secondary. Melanoma / secondary. Neoplasms / pathology. Neuroblastoma / secondary. Orbital Neoplasms / secondary. Sarcoma / secondary
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Tomography, X-Ray Computed


21. Apostolopoulos K, Ferekidis E: Extensive primary Ewings' sarcoma in the greater wing of the sphenoid bone. ORL J Otorhinolaryngol Relat Spec; 2003 Jul-Aug;65(4):235-7
Genetic Alliance. consumer health - Ewing's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive primary Ewings' sarcoma in the greater wing of the sphenoid bone.
  • We describe a rare case of an extensive primary cranial Ewing's sarcoma located in the greater wing of the sphenoid bone with extension to the orbit, the endocranium, the parapharyngeal and infratemporal space.
  • The prognosis of Ewing's sarcoma in the absence of surgery is uncertain, but prompt treatment appears to have a satisfactory therapeutic outcome.
  • In the future, more cases should be studied in order to investigate the biological behaviour of a primary cranial Ewing's sarcoma.
  • [MeSH-major] Sarcoma, Ewing / diagnosis. Sarcoma, Ewing / drug therapy. Skull Neoplasms / diagnosis. Skull Neoplasms / drug therapy. Sphenoid Bone / pathology
  • [MeSH-minor] Adult. Cranial Fossa, Middle / pathology. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Orbit / pathology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 14564101.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


22. Rénard C, Girard S, Pracros JP, Dijoud F, André JM, Mialou V, Bertrand Y: [Granulocytic sarcoma, a diagnostic challenge: 3 pediatric cases]. Arch Pediatr; 2010 Feb;17(2):149-53
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Granulocytic sarcoma, a diagnostic challenge: 3 pediatric cases].
  • [Transliterated title] Le sarcome granulocytaire, un diagnostic à connaître : à propos de 3 observations pédiatriques.
  • Granulocytic sarcoma (GS) is a rare extramedullary tumor frequently associated with acute myeloblastic leukemia (AML).
  • We report 3 cases of pediatric granulocytic sarcomas with various locations: skin, orbit, and bowel.
  • In all 3 cases, the diagnosis was delayed or initially missed.
  • GS is treated with chemotherapy, like AML.
  • [MeSH-major] Facial Neoplasms / diagnosis. Intestinal Neoplasms / diagnosis. Intestine, Small. Leukemia, Myeloid, Acute / diagnosis. Neoplasms, Multiple Primary / diagnosis. Orbital Neoplasms / diagnosis. Sarcoma, Myeloid / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Biopsy. Bone Marrow / pathology. Bone Marrow Transplantation. Child, Preschool. Combined Modality Therapy. Diagnostic Errors. Female. Follow-Up Studies. Humans. Infant. Leukemia, Biphenotypic, Acute / diagnosis. Leukemia, Biphenotypic, Acute / drug therapy. Leukemia, Biphenotypic, Acute / pathology. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 19945260.001).
  • [ISSN] 1769-664X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


23. Guzowski M, Tumuluri K, Walker DM, Maloof A: Primary orbital Ewing sarcoma in a middle-aged man. Ophthal Plast Reconstr Surg; 2005 Nov;21(6):449-51
Genetic Alliance. consumer health - Ewing's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary orbital Ewing sarcoma in a middle-aged man.
  • A 54-year-old man presented with a painful left proptosis and a soft tissue mass at the inferolateral aspect of the left orbit with bone involvement.
  • Both light microscopy and immunohistochemistry were required for the diagnosis of Ewing sarcoma.
  • After failure of chemotherapy alone, management included extensive surgical excision and postoperative adjuvant radiotherapy and chemotherapy.
  • Although rare, Ewing sarcoma should be included in the differential diagnosis of uniform round cell orbital tumors in adults.
  • [MeSH-major] Orbital Neoplasms / diagnosis. Sarcoma, Ewing / diagnosis
  • [MeSH-minor] Biopsy. Combined Modality Therapy. Diagnosis, Differential. Fatal Outcome. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304525.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. El Khorassani M, Benbrahim F, Hessissen L, Khattab M, Msefer F: [Intracerebral granulocytic sarcoma. A case report]. Neurochirurgie; 2003 May;49(2-3 Pt 1):119-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intracerebral granulocytic sarcoma. A case report].
  • Granulocytic sarcoma is a tumor composed of proliferating myeloblastic cells, generally found in the orbit.
  • After 21 months of complete remission, he developed headache and facial palsy.
  • A new medullar and cerebro-meningeal remission was obtained with chemotherapy and radiotherapy.
  • CSF and the bone marrow studies can help avoid stereotaxic biopsy can be avoided in this type of tumor
  • [MeSH-major] Brain Stem Neoplasms / radiography. Leukemia, Myeloid, Acute / complications. Sarcoma, Myeloid / radiography
  • [MeSH-minor] Bone Marrow / pathology. Child. Combined Modality Therapy. Contrast Media. Diagnosis, Differential. Humans. Male. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12746729.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


25. Rodríguez-Velasco A, Fermán-Cano F, Cerecedo-Díaz F: Rare tumor of the tongue in a child: alveolar soft part sarcoma. Pediatr Dev Pathol; 2009 Mar-Apr;12(2):147-51
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare tumor of the tongue in a child: alveolar soft part sarcoma.
  • Alveolar soft part sarcoma (ASPS) is a rare, malignant tumor of uncertain histogenesis that has no benign counterpart.
  • In contrast, the most common sites of occurrence in infants and children are the orbit (41%) and the tongue (25%).
  • The primary therapeutic option is a complete surgical excision.
  • Because of the indolent growth and lack of pain associated with the mass, 20% of patients have metastases at the time of initial diagnosis.
  • Median survival time reported for all sites of the body is 79 months.
  • The utility of adjuvant chemotherapy or radiation therapy in children is open to question.
  • [MeSH-major] Sarcoma / pathology. Soft Tissue Neoplasms / pathology. Tongue Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Child, Preschool. Cyclophosphamide / therapeutic use. Dactinomycin / therapeutic use. Disease-Free Survival. Female. Humans. Vimentin / analysis. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Alveolar Soft Part Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18630993.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vimentin; 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VAC protocol
  •  go-up   go-down


26. Modritz D, Ladenstein R, Pötschger U, Amman G, Dieckmann K, Horcher E, Urban C, Meister B, Schmitt K, Jones R, Kaulfersch W, Haas H, Moser R, Stöllinger O, Peham M, Gadner H, Koscielniak E, Treuner J: Treatment for soft tissue sarcoma in childhood and adolescence. Austrian results within the CWS 96 study. Wien Klin Wochenschr; 2005 Mar;117(5-6):196-209
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment for soft tissue sarcoma in childhood and adolescence. Austrian results within the CWS 96 study.
  • OBJECTIVE: The aim of the CWS 96 Study was to achieve an optimal treatment in children and adolescents with soft tissue sarcoma (STS) implementing a further refinement of risk-adapted allocation to chemotherapy, surgery and radiotherapy.
  • METHODS: Treatment stratification was based on tumour histology, TNM status, postsurgical stage, localisation and age.
  • 59/89 patients had localised RMS-like (rhabdomayosarcoma) STS (EFS 73% +/- 7%), 14 had localised NON-RMS STS (EFS 54% +/- 16%) and 15 patients had metastatic disease at diagnosis (EFS 33% +/- 12%), 1 patient had fibromatosis.
  • Favourable primary tumour sites of nonmetastatic RMS-like STS i.e. orbit, head/neck nonparameningeal or genitourinary non-bladder/prostate were diagnosed in 15 patients (1/15 patients died).
  • The most common treatment failure was local relapse occurring in 21% of patients in the high-risk group.
  • CONCLUSION: Risk-adapted individualisation of treatment led to a reduction of chemotherapy in the low and standard risk group without compromising survival.
  • These preliminary results after a median observation time of 2.5 years confirm the CWS 96 strategy.
  • [MeSH-major] Risk Assessment / methods. Sarcoma / mortality. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Austria / epidemiology. Child. Child, Preschool. Cohort Studies. Disease-Free Survival. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Prognosis. Risk Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Wien Klin Wochenschr. 2005 Mar;117(5-6):176-9 [15875755.001]
  • (PMID = 15875759.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


27. Hosokawa S, Takebayashi S, Mineta H, Suzuki K, Baba S: Undifferentiated sarcoma of the maxillary sinus: report of a rare case in an adult. Auris Nasus Larynx; 2009 Feb;36(1):92-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Undifferentiated sarcoma of the maxillary sinus: report of a rare case in an adult.
  • A giant solid tumor in the left maxillary sinus was detected on head CT and MRI, and this tumor was destroying the maxilla and extending into the orbit, pterygoid muscle and posterior paranasal sinuses.
  • We accordingly diagnosed undifferentiated sarcoma in the maxillary sinus.
  • Combination chemotherapy with vincristine, doxorubicin, cyclophosphamide/ifosfamide with mesna and etoposide was administered; however, the tumor was unresponsive and the patient died after around 3 months.
  • [MeSH-major] Maxillary Sinus Neoplasms / pathology. Sarcoma / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Humans. Ifosfamide / administration & dosage. Male. Mesna / administration & dosage. Middle Aged. Protective Agents / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18614305.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Protective Agents; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


28. Cecchetto G, Carretto E, Bisogno G, Dall'Igna P, Ferrari A, Scarzello G, Donfrancesco A, Alaggio R, Indolfi P, Carli M: Complete second look operation and radiotherapy in locally advanced non-alveolar rhabdomyosarcoma in children: A report from the AIEOP soft tissue sarcoma committee. Pediatr Blood Cancer; 2008 Nov;51(5):593-7
Genetic Alliance. consumer health - Soft tissue sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete second look operation and radiotherapy in locally advanced non-alveolar rhabdomyosarcoma in children: A report from the AIEOP soft tissue sarcoma committee.
  • PROCEDURE: We analyzed data from 39 patients (age: 0.5-194 months, median 52) who were enrolled between 1988 and 2005 in 2 consecutive Italian Studies, RMS 88 and RMS 96.
  • All achieved a complete resection of the residual tumor after neoadjuvant chemotherapy; 27 did not receive any other local treatment: pelvic 8, extremities 6, head-neck-non-parameningeal 5, orbit 1, genito-urinary-bladder-prostate 3, trunk 2, abdomen 1, vagina 1; 12 were given RT (32-45 Gy), 5 before and 7 after the operation: genito-urinary-bladder-prostate 3, pelvic 3, abdominal 1, extremities 1, head-neck-parameningeal 1, head-neck-non-parameningeal 1, vagina 1, orbit 1.
  • All received postoperative chemotherapy.
  • Without RT: 16/27 maintained the first complete remission, however 1/16 died due to a second tumor; 8 suffered from local relapse (4 pelvic, 1 orbit, 1 vagina, 1 head-neck-non-parameningeal, 1 abdomen) and 3 of them died, 3 showed a metastatic recurrence (2 extremities, 1 pelvic) and 1 died.
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Child. Child, Preschool. Clinical Trials as Topic. Combined Modality Therapy. Female. Humans. Infant. Kaplan-Meier Estimate. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Radiotherapy, Adjuvant. Sarcoma

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18668515.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


29. Savar A, Trent J, Al-Zubidi N, Huh W, Anderson P, Shinder R, Esmaeli B: Efficacy of adjuvant and neoadjuvant therapies for adult orbital sarcomas. Ophthal Plast Reconstr Surg; 2010 May-Jun;26(3):185-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of adjuvant and neoadjuvant therapies for adult orbital sarcomas.
  • PURPOSE: To report a series of adults with orbital soft tissue sarcoma treated with various combinations of chemotherapy, radiation therapy, and surgery and to report on the efficacy of neoadjuvant therapy in these patients.
  • METHODS: The medical records of adults who presented to our institution with orbital soft tissue sarcoma between 2003 and 2008 were reviewed.
  • Outcome measures reviewed included response to chemotherapy, type of surgery, length of follow-up, visual acuity at last follow-up, local recurrence, distant metastasis, disease-free interval, and death.
  • Nine had primary orbital lesions, 1 had a locally recurrent orbital lesion, 1 had a secondary tumor extending from the paranasal sinuses, and 2 had metastases in the orbit from primary tumors at other sites.
  • Six patients (46%) had chemotherapy, and 10 (77%) had external-beam radiation therapy; 12 patients (92%) underwent surgical resection.
  • The mean follow-up time for all patients was 26 months (range, 2 months -7 years).
  • Three patients (23%) received preoperative chemotherapy with or without radiation therapy.
  • Two of these patients underwent globe-preserving surgery, and 1 required an orbital exenteration due to the extent of disease even after chemoreduction.
  • CONCLUSION: Adults with orbital sarcomas may benefit from preoperative chemotherapy with or without radiation therapy.
  • Multidisciplinary care with involvement of medical oncologists and radiation oncologists who are familiar with sarcoma chemotherapy and radiation may benefit these patients.
  • [MeSH-major] Chemotherapy, Adjuvant. Neoadjuvant Therapy. Orbital Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Adult. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Ophthalmologic Surgical Procedures. Radiotherapy. Survival Rate. Treatment Outcome. Visual Acuity / physiology. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ophthal Plast Reconstr Surg. 2011 Mar-Apr;27(2):142; author reply 142-3 [20966791.001]
  • (PMID = 20489544.001).
  • [ISSN] 1537-2677
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Khairy-Shamel ST, Shatriah I, Adil H, Zunaina E, Bakiah S, Rohaizan Y, Hasnan J: Orbital rhabdomyosarcoma in an HIV positive child. Orbit; 2008;27(5):388-90
MedlinePlus Health Information. consumer health - HIV/AIDS.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital rhabdomyosarcoma in an HIV positive child.
  • We reported a case of orbital rhabdomyosarcoma with an intracranial extension in an HIV-infected child.
  • It was an uncommon sarcoma in a retroviral-positive patient that resulted in a diagnostic and therapeutic dilemma.
  • The child is currently asymptomatic following surgery, chemotherapy, and reinstitution of highly active retroviral therapy (HAART).
  • [MeSH-major] Brain Neoplasms / pathology. HIV Infections / transmission. Infectious Disease Transmission, Vertical. Orbital Neoplasms / pathology. Paranasal Sinus Neoplasms / pathology. Rhabdomyosarcoma, Embryonal / pathology
  • [MeSH-minor] Antiretroviral Therapy, Highly Active. CD4-CD8 Ratio. Child. Craniotomy. Humans. Male. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18836940.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. Potter BO, Sturgis EM: Sarcomas of the head and neck. Surg Oncol Clin N Am; 2003 Apr;12(2):379-417
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With the exception of pediatric RMS, soft tissue sarcomas only rarely arise in the head and neck region.
  • Soft tissue sarcomas include a diverse array of histologic types because of the variety of mesenchymal tissues from which they originate.
  • The combination of infrequent occurrence, varied pathologic features, and the many potential sites of presentation makes these tumors a challenge for the head and neck oncologist and underscore the need for review by a pathologist experienced with soft tissue tumors.
  • Although local control of the primary tumor is critical to successful treatment of both high- and low-grade lesions, the high rate of distant metastases in high-grade tumors supports the role of combined modality therapy.
  • Compared with other types of head and neck neoplasms, such as squamous cell carcinoma, soft tissue sarcomas have low rates of regional metastases.
  • Surgery generally has been recommended as the primary method of treatment for achieving local control, except in those high-grade tumors arising in sites not amenable to resection.
  • Exceptions to this principle include RMSs of the orbit, paranasal sinuses, and masticator space in children; these are usually treated with radiotherapy and combined multiagent chemotherapy, thereby avoiding the functional and cosmetic impact of surgery.
  • Also, extensive angiosarcomas of the scalp should be treated with multimodality therapy combining surgery and wide-field radiation therapy in an attempt to achieve local control.
  • Systemic chemotherapy is recommended for those tumors with a significant risk of distant metastases.
  • Increasingly, neoadjuvant chemotherapy is being used to determine responsiveness to chemotherapy, which can help physicians select patients who may benefit from systemic postoperative therapy.
  • Traditional predictors of treatment failure for soft tissue sarcomas include larger tumor size, high-grade histology, and positive surgical margins.
  • The advent of more advanced reconstructive techniques, including free tissue transfer, has made more aggressive surgical resection of these tumors possible.
  • In the future, the discovery of the molecular pathogenesis of specific tumor types, such as the cytogenetic findings in synovial sarcoma, will improve physicians' prognostic abilities and selection of patients who are most likely to benefit from emerging adjuvant therapies.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Sarcoma / pathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12916461.001).
  • [ISSN] 1055-3207
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 183
  •  go-up   go-down


32. Donaldson SS, Meza J, Breneman JC, Crist WM, Laurie F, Qualman SJ, Wharam M, Children's Oncology Group Soft Tissue Sarcoma Committee (formely Intergroup Rhabdomyosarcoma Group) representing the Children's Oncology Group and the Quality Assurance Review Center: Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma--a report from the IRSG. Int J Radiat Oncol Biol Phys; 2001 Nov 1;51(3):718-28
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 490 remaining, 239 were randomized to HFRT (59.4 Gy in 54 1.1-Gy twice daily fractions) and 251 to CFRT (50.4 Gy in 28 1.8-Gy daily fractions).
  • All patients received chemotherapy.
  • RT began at Week 9 after induction chemotherapy for all but those with high-risk parameningeal tumors who received RT during induction chemotherapy.
  • RESULTS: Analysis by randomized treatment assignment (intent to treat) revealed an estimated 5-year failure-free survival (FFS) rate of 70% and overall survival (OS) of 75%.
  • In the univariate analysis, the factors associated with the best outcome were age 1-9 years at diagnosis; noninvasive tumors; tumor size <5 cm; uninvolved lymph nodes; Stage 1 or 2 disease; primary site in the orbit or head and neck; and embryonal histologic features (p = 0.001 for all factors).
  • No differences in the FFS or OS between the two RT treatment methods and no differences in the FFS or OS between HFRT and CFRT were found when analyzed by age, gender, tumor size, tumor invasiveness, nodal status, histologic features, stage, or primary site.
  • Treatment compliance differed by age.
  • Of the children >or=5 years, 88% assigned to both HFRT and CFRT received their assigned treatment.
  • The reasons for not receiving the appropriate randomized treatment were progressive disease, early death, parent or physician refusal, young age, or surgery.
  • The analysis by treatment actually received revealed a 5-year FFS rate of 73% and OS rate of 77%, with no difference between CFRT and HFRT.
  • The 5-year local failure rate by site was orbit, 5%; head and neck, 12%; parameningeal, 16%; bladder/prostate, 19%; extremity, 7%; and all others, 14%.
  • The 5-year distant failure rate was orbit, 2%; head and neck, 6%; parameningeal, 11%; bladder/prostate, 15%; extremity, 28%; and all others, 17%.
  • The standard of care for Group III RMS continues to be CFRT with chemotherapy.
  • [MeSH-minor] Adolescent. Adult. Analysis of Variance. Child. Child, Preschool. Female. Humans. Infant. Male. Patient Compliance. Radiation Injuries / classification. Radiation Injuries / pathology. Remission Induction. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1579-80; author reply 1580 [12459396.001]
  • (PMID = 11597814.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-24507
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


33. Kobayashi R, Tawa A, Hanada R, Horibe K, Tsuchida M, Tsukimoto I, Japanese childhood AML cooperative study group: Extramedullary infiltration at diagnosis and prognosis in children with acute myelogenous leukemia. Pediatr Blood Cancer; 2007 Apr;48(4):393-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramedullary infiltration at diagnosis and prognosis in children with acute myelogenous leukemia.
  • PROCEDURE: We evaluated the frequency and prognostic significance of EMI at diagnosis of AML in children.
  • RESULTS: Of 240 cases of de novo AML excluding children with Down syndrome and acute promyelocytic leukemia, 56 (23.3%) showed EMI at diagnosis.
  • The complete remission rate following induction chemotherapy was lower in patients with EMI.
  • A detailed analysis showed that patients with EMI with a WBC count at diagnosis of over 100 x 10(9)/L or infiltration into the central nervous system are likely to have a poor prognosis.
  • CONCLUSIONS: CNS leukemia and EMI together with a WBC count of >100 x 10(9)/L at diagnosis of AML are high risk factors for relapse, and alternative treatment approaches for patients with these characteristics should be explored.
  • [MeSH-major] Leukemia, Myeloid / pathology. Leukemic Infiltration / epidemiology. Sarcoma, Myeloid / epidemiology
  • [MeSH-minor] Acute Disease. Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone and Bones / pathology. Central Nervous System / pathology. Child. Child, Preschool. Cytarabine / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Follow-Up Studies. Gingiva / pathology. Humans. Hydrocortisone / administration & dosage. Idarubicin / administration & dosage. Infant. Infant, Newborn. Japan / epidemiology. Kaplan-Meier Estimate. Male. Methotrexate / administration & dosage. Orbit / pathology. Prognosis. Remission Induction. Skin / pathology. Testis / pathology

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550530.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate; ZRP63D75JW / Idarubicin
  •  go-up   go-down


34. Durisin M, Mengel M, Beilken A, Donnerstag F, Lenarz T, Stöver T: [Embryonal rhabdomyosarcoma of the orbita]. Laryngorhinootologie; 2006 Feb;85(2):124-7
Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 2(1/2) year old girl was presented with an acute, painless orbital swelling without signs of local or systemic inflammation.
  • By means of this case we present the current diagnostic and therapeutic approaches for childhood soft tissue sarcomas.
  • At present our patient receives a poly-chemotherapy which has already shown a good response.
  • This case demonstrates that in a child with a unilateral, progressive orbital tumor, the differential diagnosis of a soft tissue sarcoma has to be ruled out.
  • [MeSH-major] Orbital Neoplasms. Rhabdomyosarcoma, Embryonal
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Child, Preschool. Diagnosis, Differential. Exophthalmos / etiology. Female. Humans. Orbit / pathology. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498541.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


35. Day TA, Beas RA, Schlosser RJ, Woodworth BA, Barredo J, Sharma AK, Gillespie MB: Management of paranasal sinus malignancy. Curr Treat Options Oncol; 2005 Jan;6(1):3-18
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignancies of the nasal cavity and paranasal sinuses represent a wide spectrum of histologies, tissues of origin, and anatomic primary sites.
  • The inherent difficulty in generalizing treatment approaches is obvious, given the numerous variables associated with the broadly-based term, paranasal sinus malignancy (PNSCa).
  • Nevertheless, the majority of epithelial and salivary malignancies of this region (ie, squamous cell carcinoma, adenocarcinoma, adenoid cystic carcinoma, sinonasal undifferentiated carcinoma, and esthesioneuroblastoma) require surgical intervention as part of any treatment regimen.
  • Nonepithelial malignancies, including the wide variety of sarcomas arising in this region, most commonly require multimodality treatment including chemotherapy, radiation, and/or surgery for definitive treatment.
  • Moreover, the proximity of the nasal cavity and paranasal sinuses to structures including the orbit, dura, brain, cranial nerves, and carotid arteries mandates careful radiologic and neurologic evaluations throughout the course of the disease.
  • However, additional clinical trials are necessary to systematically evaluate the locoregional control, organ-preservation strategies, and survival related to the variety of treatments currently available.
  • [MeSH-major] Carcinoma / surgery. Melanoma / surgery. Paranasal Sinus Neoplasms / surgery. Sarcoma / surgery
  • [MeSH-minor] Adult. Age Factors. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Diet. Humans. Life Style. Prognosis. Radiotherapy, Adjuvant. Reconstructive Surgical Procedures

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):486-91 [12243826.001]
  • [Cites] Head Neck. 1995 Jul-Aug;17(4):303-11 [7672971.001]
  • [Cites] Laryngoscope. 1999 Oct;109(10):1539-43 [10522919.001]
  • [Cites] Med Pediatr Oncol. 1999 Oct;33(4):362-71 [10491544.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):335-41 [14716769.001]
  • [Cites] Cancer J Sci Am. 1999 Jul-Aug;5(4):219-23 [10439167.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):371-6 [11859210.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Aug;130(8):948-55 [15313865.001]
  • [Cites] Head Neck Surg. 1980 May-Jun;2(5):410-9 [7364592.001]
  • [Cites] Am J Otolaryngol. 2004 May-Jun;25(3):162-6 [15124164.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1157-62 [11583200.001]
  • [Cites] Oral Oncol. 2002 Jul;38(5):450-9 [12110339.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jul 15;128(2):130-6 [11463451.001]
  • [Cites] Laryngoscope. 2002 Oct;112(10):1871-6 [12368633.001]
  • [Cites] Oncology (Williston Park). 2000 Nov;14(11A):163-94 [11195409.001]
  • [Cites] Otolaryngol Clin North Am. 1995 Dec;28(6):1239-57 [8927395.001]
  • [Cites] Otolaryngol Head Neck Surg. 2003 Jul;129(1):77-84 [12869921.001]
  • [Cites] Otolaryngol Clin North Am. 2004 Apr;37(2):473-87 [15064075.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Jul;128(7):751-8 [12117328.001]
  • [Cites] Nature. 1987 Oct 15-21;329(6140):645-7 [3657988.001]
  • [Cites] Am J Rhinol. 2002 Jul-Aug;16(4):221-7 [12222948.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):158-68 [12694834.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1991 Mar;3(2):84-9 [2031888.001]
  • [Cites] Am J Rhinol. 2002 Sep-Oct;16(5):281-6 [12422974.001]
  • [Cites] Stereotact Funct Neurosurg. 2004;82(2-3):84-9 [15305080.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Sep;129(9):944-8 [12975266.001]
  • [Cites] Oncology (Williston Park). 1992 Jan;6(1):43-50; discussion 55-6 [1531603.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):361-9 [9607352.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):283-9 [9308929.001]
  • [Cites] Ear Nose Throat J. 2002 Aug;81(8):510-4, 516-7 [12199167.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):594-611 [12717245.001]
  • [Cites] Laryngoscope. 2000 Apr;110(4):635-40 [10764010.001]
  • [Cites] Med Pediatr Oncol. 2001 Feb;36(2):290-4 [11452937.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jul 1;136(1):53-7 [12165452.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1405-10 [11870186.001]
  • [Cites] Strahlenther Onkol. 2003 Apr;179(4):233-40 [12707712.001]
  • [Cites] Head Neck. 2004 Feb;26(2):136-44 [14762882.001]
  • [Cites] Acta Otolaryngol. 2002 Mar;122(2):197-201 [11936913.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):204-13 [10623711.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Jul;119(7):743-6 [8318204.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):147-54 [14697432.001]
  • [Cites] Minim Invasive Neurosurg. 2004 Feb;47(1):9-15 [15100926.001]
  • [Cites] Acta Otorhinolaryngol Belg. 1996;50(1):19-24 [8669267.001]
  • [Cites] Laryngoscope. 2003 Dec;113(12):2086-90 [14660907.001]
  • [Cites] Am J Surg Pathol. 1986 Mar;10 (3):192-202 [3953940.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5108-12 [8221646.001]
  • [Cites] Head Neck. 2004 May;26(5):435-41 [15122660.001]
  • [Cites] Head Neck. 2003 Oct;25(10):791-8 [12966502.001]
  • [Cites] Head Neck Surg. 1980 Jul-Aug;2(6):497-508 [6248488.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1023-7; discussion 1027-8 [9588546.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3012-29 [11753979.001]
  • [Cites] Acta Otorhinolaryngol Belg. 2000;54(2):221-32 [10892511.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1991 Jan;3(1):17-21 [1705815.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Nov 1;39(4):823-9 [9369129.001]
  • [Cites] Epidemiology. 1998 Sep;9(5):518-24 [9730030.001]
  • [Cites] Eur J Nucl Med. 2001 Jul;28(7):816-21 [24770459.001]
  • [Cites] J Laryngol Otol. 1992 Dec;106(12):1063-6 [1487661.001]
  • [Cites] J Neurosurg. 1995 Jun;82(6):1002-10 [7760173.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1937-44 [15128893.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Sep;128(9):1079-83 [12220216.001]
  • [Cites] Laryngoscope. 2002 Aug;112(8 Pt 1):1450-5 [12172261.001]
  • [Cites] Cancer J Sci Am. 1999 Jul-Aug;5(4):208-10 [10439164.001]
  • [Cites] Head Neck. 1994 Nov-Dec;16(6):574-7 [7822181.001]
  • [Cites] Hum Pathol. 2003 Nov;34(11):1101-7 [14652810.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Mar;129(3):334-7 [12622544.001]
  • [Cites] Cancer. 1999 Nov 1;86(9):1700-11 [10547542.001]
  • [Cites] Head Neck. 2004 Apr;26(4):322-30 [15054735.001]
  • [Cites] Cancer. 1992 Feb 1;69(3):657-61 [1730116.001]
  • [Cites] Cancer. 1999 Jul 15;86(2):255-64 [10421261.001]
  • [Cites] J Laryngol Otol. 1998 Jul;112(7):628-33 [9775291.001]
  • [Cites] Head Neck. 2002 Sep;24(9):821-9 [12211046.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5C):3743-9 [11268448.001]
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] Head Neck. 2004 Jul;26(7):584-93 [15229900.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Jan;13(1):167-86 [15062368.001]
  • [Cites] Cancer Causes Control. 2002 Mar;13(2):147-57 [11936821.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):92-8 [12506176.001]
  • [Cites] Otolaryngol Head Neck Surg. 1999 Mar;120(3):387-90 [10064643.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1945-52 [15128894.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):776-84 [12573765.001]
  • [Cites] Radiother Oncol. 1991 Jul;21(3):193-200 [1924855.001]
  • [Cites] Laryngoscope. 1992 Aug;102(8):843-9 [1495347.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] J Clin Pathol. 2004 Sep;57(9):932-7 [15333652.001]
  • [Cites] Cancer. 2003 Apr 25;99(2):105-12 [12704690.001]
  • [Cites] Otolaryngol Clin North Am. 2001 Dec;34(6):1241-57, xi [11728944.001]
  • [Cites] Am J Epidemiol. 1994 Aug 15;140(4):340-9 [8059769.001]
  • [Cites] Ann Oncol. 2003 Mar;14(3):367-72 [12598339.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1597-604 [12459626.001]
  • [Cites] Laryngoscope. 2002 Nov;112(11):1964-9 [12439163.001]
  • [Cites] Am J Ind Med. 1999 Jul;36(1):101-7 [10361593.001]
  • [Cites] Minim Invasive Neurosurg. 2004 Feb;47(1):1-8 [15100925.001]
  • [Cites] Minim Invasive Neurosurg. 2003 Oct;46(5):310-5 [14628249.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):318-31 [11567805.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1029-37 [9588547.001]
  • (PMID = 15610711.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 99
  •  go-up   go-down


36. Meza JL, Anderson J, Pappo AS, Meyer WH, Children's Oncology Group: Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. J Clin Oncol; 2006 Aug 20;24(24):3844-51
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The outcome for localized rhabdomyosarcoma (RMS) or undifferentiated sarcoma (UDS) is affected by age, histology, primary anatomic site, extent of disease, and therapy.
  • RESULTS: The estimated 5-year failure-free survival (FFS) rate was 90% for patients with embryonal RMS (ERMS) stage 1, group I or IIa; stage 2, group I; or group III orbit.
  • CONCLUSION: Patient and disease characteristics identify distinct subsets with different outcomes, allowing the Soft Tissue Sarcoma Committee of the Children's Oncology Group to refine risk-adapted therapy assignment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rhabdomyosarcoma / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Infant. Infusions, Intravenous. Male. Neoplasm Staging. Predictive Value of Tests. Prognosis. Risk Assessment. Risk Factors. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16921036.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-24507; United States / NCI NIH HHS / CA / CA-72989
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down






Advertisement